SciVision Biotech (1786) Fundamentals 2026 — P/E 28.7x, Revenue Analysis | SniperIQ
SciVision Biotech (1786) is a TW-listed Healthcare company in Medical - Devices with a market capitalization of NT
SciVision Biotech (1786) has a market capitalization of approximately NT
SciVision Biotech's trailing twelve-month P/E ratio is 28.7x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
SciVision Biotech runs a net profit margin of 14.4%, a gross margin of 71.0%, and an operating margin of 17.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
SciVision Biotech reported revenue of NT$887M for fiscal year 2025, with net income of NT
SciVision Biotech offers a trailing dividend yield of about 3.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
SciVision Biotech carries a debt-to-equity ratio of 0.26x and a current ratio of 4.09x, with a market beta of 0.40. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SciVision Biotech (1786) the key facts are: market cap NT
Get SciVision Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.